Iridex Corporation (IRIX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
IRIX Chart
IRIDEX Corporation, Inc. (IRIX) Q1 2025 Earnings Call Transcript
IRIDEX Corporation, Inc. (NASDAQ:IRIX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Trip Taylor - IR Patrick Mercer - CEO, President & Director Romeo Dizon - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Iridex Reports First Quarter 2025 Financial Results
MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025.
IRIDEX Changes Course
IRIDEX's strategic review ended without a major asset sale, but a $10M investment from Novel Inspiration International offers growth potential and cash stability. Novel's investment values IRIDEX shares at $2.00/share, significantly higher than current trading prices, indicating a belief in the company's undervaluation. The recent LCD change in glaucoma treatment reimbursement could significantly boost IRIDEX's glaucoma business, potentially increasing the company's market valuation.
Iridex Corporation Dividends
Iridex Corporation Earnings
| 7 Aug 2025 (58 Days) Date | | - Cons. EPS | - EPS |
| 18 Jun 2025 (8 Days) Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 18 Jun 2024 Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 (58 Days) Date | | - Cons. EPS | - EPS |
| 18 Jun 2025 (8 Days) Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 18 Jun 2024 Date | | - Cons. EPS | - EPS |
Iridex Corporation (IRIX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Iridex Corporation ever had a stock split?
Iridex Corporation Profile
| Medical - Devices Industry | Healthcare Sector | Mr. Patrick Mercer CEO | NASDAQ (CM) Exchange | 462684101 Cusip |
| US Country | 93 Employees | - Last Dividend | - Last Split | 15 Feb 1996 IPO Date |
Overview
IRIDEX Corporation is an ophthalmic medical technology company at the forefront of developing and providing innovative laser systems, delivery devices, and consumable instrumentation designed to treat sight-threatening eye diseases in the field of ophthalmology. With its roots going back to 1989 and originally known as IRIS Medical Instruments, Inc., the company underwent a name change to IRIDEX Corporation in November 1995. From its headquarters in Mountain View, California, IRIDEX has committed itself to serve ophthalmologists, research and teaching hospitals, government installations, surgical centers, veterinary practices, and office clinics both in the United States and internationally. Products are marketed directly as well as through a network of independent distributors worldwide, demonstrating their global reach and commitment to addressing eye health.
Products and Services
IRIDEX Corporation offers a wide range of high-quality ophthalmic laser systems and accessories designed for various treatments. Here are some of their key products and services:
- Cyclo G6 Laser System: Designed for the treatment of glaucoma, this system represents a pivotal advancement in managing a condition that can lead to severe vision impairment or blindness.
- IQ 532 and IQ 577 Laser Systems: These systems are utilized for the treatment of retinal disorders, providing precise and effective therapy options for patients suffering from conditions like diabetic retinopathy.
- OcuLight Laser Photocoagulation Systems (TX, SL, SLx, GL, GLx): A series of lasers used to treat a range of issues including proliferative diabetic retinopathy, macular holes, retinal tears, and detachments, offering versatile solutions in the management of retinal diseases.
- TxCell Scanning Laser Delivery System: This device enables physicians to perform multi-spot pattern scanning, enhancing the efficiency and coverage of laser treatments.
- Slit Lamp Adapter: Allows the integration of a standard slit lamp with laser systems for diagnostic and treatment procedures, thereby expanding the utility of existing equipment in clinics and hospitals.
- Laser Indirect Ophthalmoscope: Facilitates procedures to treat peripheral retinal disorders, ensuring comprehensive care for patients with complex retinal conditions.
- MicroPulse P3 Probe: Used with the Cyclo G6 system, this probe allows for MicroPulse transscleral laser therapy, a tissue-sparing option for treating glaucoma.
- G-Probe and G-Probe Illuminate: These probes are essential for procedures aimed at treating uncontrolled and refractory glaucoma, showcasing IRIDEX's commitment to innovative glaucoma management solutions.
- EndoProbe Family of Products: Designed for use in vitrectomy procedures, these products highlight IRIDEX's contribution to advanced surgical options for eye diseases.
IRIDEX's commitment to innovation is evident in their comprehensive range of products and services designed to meet the needs of ophthalmologists and their patients globally.
Contact Information
